Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice

Richard Bachelier, Xiaoling Xu, Xaoyan Wang, Wenmei Li, Mayumi Naramura, Hua Gu, Chu Xia Deng

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Breast-cancer-associated gene 1 (BRCA1) is highly expressed in thymus and spleen. In this paper, we have studied lymphocyte development and tumorigenesis in mice carrying mutations in Brca1 and p53. We show that the deletion of Brca1 exon 11 (Brca1-Δ11), which disrupts the full-length isoform, but not the short isoform of Brca1, does not interfere with lymphocyte development. This is true irrespective of p53 status, that is, whether it is wild type, heterozygous or homozygous for a null mutation. These data suggest that the expression of Brca1 short isoform alone is enough to maintain normal development of lymphocytes. However, it cannot suppress tumorigenesis as about 30% of Brca1Δ11/Δ11p53+/- mice develop thymic lymphoma between 3 and 7 months of age. We demonstrate that p53 plays an essential role in Brca1-associated lymphoma, as all the tumors from Brca1Δ11/Δ11p53+/- mice exhibit LOH of p53 and Brca1Δ11/Δ11p53-/- mice exhibited accelerated tumorigenesis. We further demonstrate that the Brca1-Δ11 deficiency does not affect thymocyte proliferation; however, it increases genetic instability and triggers γ-irradiation-induced apoptosis. The loss of p53 attenuates apoptosis and allows accumulation of further mutations in Brca1-Δ11 thymocytes, eventually leading to thymic lymphoma formation.

Original languageEnglish (US)
Pages (from-to)528-537
Number of pages10
JournalOncogene
Volume22
Issue number4
DOIs
StatePublished - Jan 30 2003

Fingerprint

Exons
Lymphoma
Lymphocytes
Protein Isoforms
Carcinogenesis
Thymocytes
Apoptosis
Mutation
Neoplasm Genes
Thymus Gland
Spleen
Breast Neoplasms
Neoplasms

Keywords

  • Brca1
  • T-lymphoma
  • Tumorigenesis
  • p53

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Bachelier, R., Xu, X., Wang, X., Li, W., Naramura, M., Gu, H., & Deng, C. X. (2003). Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. Oncogene, 22(4), 528-537. https://doi.org/10.1038/sj.onc.1206208

Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. / Bachelier, Richard; Xu, Xiaoling; Wang, Xaoyan; Li, Wenmei; Naramura, Mayumi; Gu, Hua; Deng, Chu Xia.

In: Oncogene, Vol. 22, No. 4, 30.01.2003, p. 528-537.

Research output: Contribution to journalArticle

Bachelier, R, Xu, X, Wang, X, Li, W, Naramura, M, Gu, H & Deng, CX 2003, 'Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice', Oncogene, vol. 22, no. 4, pp. 528-537. https://doi.org/10.1038/sj.onc.1206208
Bachelier, Richard ; Xu, Xiaoling ; Wang, Xaoyan ; Li, Wenmei ; Naramura, Mayumi ; Gu, Hua ; Deng, Chu Xia. / Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. In: Oncogene. 2003 ; Vol. 22, No. 4. pp. 528-537.
@article{49e54aca9ec74f43b4e1587d0c5f6e32,
title = "Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice",
abstract = "Breast-cancer-associated gene 1 (BRCA1) is highly expressed in thymus and spleen. In this paper, we have studied lymphocyte development and tumorigenesis in mice carrying mutations in Brca1 and p53. We show that the deletion of Brca1 exon 11 (Brca1-Δ11), which disrupts the full-length isoform, but not the short isoform of Brca1, does not interfere with lymphocyte development. This is true irrespective of p53 status, that is, whether it is wild type, heterozygous or homozygous for a null mutation. These data suggest that the expression of Brca1 short isoform alone is enough to maintain normal development of lymphocytes. However, it cannot suppress tumorigenesis as about 30{\%} of Brca1Δ11/Δ11p53+/- mice develop thymic lymphoma between 3 and 7 months of age. We demonstrate that p53 plays an essential role in Brca1-associated lymphoma, as all the tumors from Brca1Δ11/Δ11p53+/- mice exhibit LOH of p53 and Brca1Δ11/Δ11p53-/- mice exhibited accelerated tumorigenesis. We further demonstrate that the Brca1-Δ11 deficiency does not affect thymocyte proliferation; however, it increases genetic instability and triggers γ-irradiation-induced apoptosis. The loss of p53 attenuates apoptosis and allows accumulation of further mutations in Brca1-Δ11 thymocytes, eventually leading to thymic lymphoma formation.",
keywords = "Brca1, T-lymphoma, Tumorigenesis, p53",
author = "Richard Bachelier and Xiaoling Xu and Xaoyan Wang and Wenmei Li and Mayumi Naramura and Hua Gu and Deng, {Chu Xia}",
year = "2003",
month = "1",
day = "30",
doi = "10.1038/sj.onc.1206208",
language = "English (US)",
volume = "22",
pages = "528--537",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice

AU - Bachelier, Richard

AU - Xu, Xiaoling

AU - Wang, Xaoyan

AU - Li, Wenmei

AU - Naramura, Mayumi

AU - Gu, Hua

AU - Deng, Chu Xia

PY - 2003/1/30

Y1 - 2003/1/30

N2 - Breast-cancer-associated gene 1 (BRCA1) is highly expressed in thymus and spleen. In this paper, we have studied lymphocyte development and tumorigenesis in mice carrying mutations in Brca1 and p53. We show that the deletion of Brca1 exon 11 (Brca1-Δ11), which disrupts the full-length isoform, but not the short isoform of Brca1, does not interfere with lymphocyte development. This is true irrespective of p53 status, that is, whether it is wild type, heterozygous or homozygous for a null mutation. These data suggest that the expression of Brca1 short isoform alone is enough to maintain normal development of lymphocytes. However, it cannot suppress tumorigenesis as about 30% of Brca1Δ11/Δ11p53+/- mice develop thymic lymphoma between 3 and 7 months of age. We demonstrate that p53 plays an essential role in Brca1-associated lymphoma, as all the tumors from Brca1Δ11/Δ11p53+/- mice exhibit LOH of p53 and Brca1Δ11/Δ11p53-/- mice exhibited accelerated tumorigenesis. We further demonstrate that the Brca1-Δ11 deficiency does not affect thymocyte proliferation; however, it increases genetic instability and triggers γ-irradiation-induced apoptosis. The loss of p53 attenuates apoptosis and allows accumulation of further mutations in Brca1-Δ11 thymocytes, eventually leading to thymic lymphoma formation.

AB - Breast-cancer-associated gene 1 (BRCA1) is highly expressed in thymus and spleen. In this paper, we have studied lymphocyte development and tumorigenesis in mice carrying mutations in Brca1 and p53. We show that the deletion of Brca1 exon 11 (Brca1-Δ11), which disrupts the full-length isoform, but not the short isoform of Brca1, does not interfere with lymphocyte development. This is true irrespective of p53 status, that is, whether it is wild type, heterozygous or homozygous for a null mutation. These data suggest that the expression of Brca1 short isoform alone is enough to maintain normal development of lymphocytes. However, it cannot suppress tumorigenesis as about 30% of Brca1Δ11/Δ11p53+/- mice develop thymic lymphoma between 3 and 7 months of age. We demonstrate that p53 plays an essential role in Brca1-associated lymphoma, as all the tumors from Brca1Δ11/Δ11p53+/- mice exhibit LOH of p53 and Brca1Δ11/Δ11p53-/- mice exhibited accelerated tumorigenesis. We further demonstrate that the Brca1-Δ11 deficiency does not affect thymocyte proliferation; however, it increases genetic instability and triggers γ-irradiation-induced apoptosis. The loss of p53 attenuates apoptosis and allows accumulation of further mutations in Brca1-Δ11 thymocytes, eventually leading to thymic lymphoma formation.

KW - Brca1

KW - T-lymphoma

KW - Tumorigenesis

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0037473112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037473112&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206208

DO - 10.1038/sj.onc.1206208

M3 - Article

C2 - 12555066

AN - SCOPUS:0037473112

VL - 22

SP - 528

EP - 537

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 4

ER -